

Client: Example Client ABC123
123 Test Drive
Salt Lake City, UT 84108
UNITED STATES

Physician: Doctor, Example

Patient: Patient, Example

DOB: Unknown
Gender: Unknown
Patient Identifiers: 01234567890ABCD, 012345
Visit Number (FIN): 01234567890ABCD
Collection Date: 00/00/0000 00:00

Extended Myositis Panel

ARUP test code 3018867

SSA-52 (Ro52) (ENA) Antibody, IgG

0 AU/mL (Ref Interval: 0-40)
INTERPRETIVE INFORMATION: SSA-52 (Ro52) (ENA) Antibody, IgG

29 AU/mL or Less Negative
30 - 40 AU/mL Equivocal
41 AU/mL or Greater Positive

SSA-52 (Ro52) and/or SSA-60 (Ro60) antibodies are associated with a diagnosis of Sjogren syndrome, systemic lupus erythematosus (SLE), and systemic sclerosis. SSA-52 antibody overlaps significantly with the major SSC-related antibodies. SSA-52 (Ro52) antibody occurs frequently in patients with inflammatory myopathies, often in the presence of interstitial lung disease.

SSA-60 (Ro60) (ENA) Antibody, IgG

0 AU/mL (Ref Interval: 0-40)
REFERENCE INTERVAL: SSA-60 (Ro60) (ENA) Antibody, IgG

29 AU/mL or Less Negative
30 - 40 AU/mL Equivocal
41 AU/mL or Greater Positive

Smith/RNP (ENA) Ab, IgG

0 Units (Ref Interval: 0-19)
INTERPRETIVE INFORMATION: Smith/RNP (ENA) Antibody, IgG

19 Units or Less Negative
20 to 39 Units Weak Positive
40 to 80 Units Moderate Positive
81 Units or greater Strong Positive

Smith/RNP antibodies are frequently seen in patients with mixed connective tissue disease (MCTD) and are also associated with other systemic autoimmune rheumatic diseases (SARDs) such as systemic lupus erythematosus (SLE), systemic sclerosis, and myositis. Antibodies targeting the Smith/RNP antigenic complex also recognize Smith antigens, therefore, the Smith antibody response must be considered when interpreting these results.

Jo-1 (Histidyl-tRNA Synthetase) Ab, IgG

0 AU/mL (Ref Interval: 0-40)

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

INTERPRETIVE INFORMATION: Jo-1 Antibody, IgG

29 AU/mL or less.....Negative
30-40 AU/mL.....Equivocal
41 AU/mL or greater.....Positive

Presence of Jo-1 (antihistidyl transfer RNA [t-RNA] synthetase) antibody is associated with polymyositis and may also be seen in patients with dermatomyositis. Jo-1 antibody is associated with pulmonary involvement (interstitial lung disease), Raynaud phenomenon, arthritis, and mechanic's hands (implicated in antisynthetase syndrome).

PL-12 (alanyl-tRNA synthetase) Antibody Negative (Ref Interval: Negative)

PL-7 (threonyl-tRNA synthetase) Antibody Negative (Ref Interval: Negative)

EJ (glycyl-tRNA synthetase) Antibody Negative (Ref Interval: Negative)

OJ (isoleucyl-tRNA synthetase) Antibody Negative (Ref Interval: Negative)

SRP (Signal Recognition Particle) Ab Negative (Ref Interval: Negative)

Ku Antibody Negative (Ref Interval: Negative)

PM/Scl 100 Antibody, IgG Negative (Ref Interval: Negative)

INTERPRETIVE INFORMATION: PM/Scl-100 Antibody, IgG by Immunoblot

The presence of PM/Scl-100 IgG antibody along with a positive ANA IFA nucleolar pattern is associated with connective tissue diseases such as polymyositis (PM), dermatomyositis (DM), systemic sclerosis (SSC), and polymyositis/systemic sclerosis overlap syndrome. The clinical relevance of PM/Scl-100 IgG antibody with a negative ANA IFA nucleolar pattern is unknown. PM/Scl-100 is the main target epitope of the PM/Scl complex, although antibodies to other targets not detected by this assay may occur.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Fibrillarin (U3 RNP) Ab, IgG Negative (Ref Interval: Negative)

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

Interpretive Information: Fibrillarin (U3 RNP) Antibody, IgG

The presence of fibrillarin (U3-RNP) IgG antibodies in association with an ANA IFA nucleolar pattern is suggestive of systemic sclerosis (SSc). In SSc, these antibodies are associated with distinct clinical features, such as younger age at disease onset, frequent internal organ involvement (pulmonary hypertension, myositis and renal disease). Fibrillarin antibodies are detected more frequently in African American patients with SSc compared to other ethnic groups. Strong correlation with ANA IFA results is recommended.

In a multi-ethnic cohort of SSc patients (n=98), U3-RNP antibodies detected by immunoblot had an agreement of 98.9 percent with the gold standard immunoprecipitation (IP) assay. Approximately 71 percent (5/7) of the borderline U3-RNP results with ANA nucleolar pattern in this cohort were IP negative.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Mi-2 (nuclear helicase protein) Antibody	Negative	(Ref Interval: Negative)
--	----------	--------------------------

P155/140 Antibody	Negative	(Ref Interval: Negative)
-------------------	----------	--------------------------

TIF-1 gamma (155 kDa) Ab	Negative	(Ref Interval: Negative)
--------------------------	----------	--------------------------

SAE1 (SUMO activating enzyme) Ab	Negative	(Ref Interval: Negative)
----------------------------------	----------	--------------------------

MDA5 (CADM-140) Ab	Negative	(Ref Interval: Negative)
--------------------	----------	--------------------------

NXP2 (Nuclear matrix protein-2) Ab	Negative	(Ref Interval: Negative)
------------------------------------	----------	--------------------------

Myositis Panel Interpretive Data	See Note	
----------------------------------	----------	--

H=High, L=Low, *=Abnormal, C=Critical

INTERPRETIVE INFORMATION: Extended Myositis Panel 2

If present, myositis-specific antibodies (MSAs) are specific for myositis, and may be useful in establishing diagnosis as well as prognosis. MSAs are generally regarded as mutually exclusive with rare exceptions; the occurrence of two or more MSAs should be carefully evaluated in the context of patient's clinical presentation. Myositis-associated antibodies (MAAs) may be found in patients with CTD including overlap syndromes, and are generally not specific for myositis. The following table will help in identifying the association of any antibodies found as either MSAs or MAAs.

Antibody Specificity	MSAs	MAAs
SSA 52 (Ro) (ENA) Antibody IgG	X	
SSA 60 (Ro) (ENA) Antibody IgG	X	
Smith/RNP (ENA) Ab, IgG	X	
Jo-1 (histidyl-tRNA synthetase) Ab, IgG	X	
PL-12 (alanyl-tRNA synthetase) Antibody	X	
PL-7 (threonyl-tRNA synthetase) Antibody	X	
EJ (glycyl-tRNA synthetase) Antibody	X	
OJ (isoleucyl-tRNA synthetase) Antibody	X	
SRP (Signal Recognition Particle) Ab	X	
Ku Antibody		X
PM/SCL 100 Antibody, IgG		X
Fibrillarin (U3 RNP) Ab, IgG		X
Mi-2 (nuclear helicase protein) Antibody	X	
P155/140 Antibody	X	
TIF-1 gamma (155 kDa) Ab	X	
SAE1 (SUMO activating enzyme) Ab	X	
MDA5 (CADM-140) Ab	X	
NXP2 (Nuclear matrix proten-2)Ab	X	
Ha (tyrosyl-tRNA synthetase) Ab	X	
Ks (asparaginy1-tRNA synthetase) Ab	X	
Zo (phenylalanyl-tRNA synthetase) Ab	X	

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Antinuclear Antibody (ANA), HEp-2, IgG <1:80 (Ref Interval: <1:80)

ANA Interpretive Comment

See Note

Antinuclear antibodies by IFA negative for homogeneous, speckled, nucleolar, centromere, and nuclear dots patterns.
Cytoplasmic antibodies by IFA negative for reticular/AMA, discrete/GW body-like, polar/golgi-like, rods and rings, and cytoplasmic speckled patterns.

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

INTERPRETIVE INFORMATION: ANA Interpretive Comment

Presence of antinuclear antibodies (ANA) is a hallmark feature of systemic autoimmune rheumatic diseases (SARD). However, ANA lacks diagnostic specificity and is associated with a variety of diseases (cancers, autoimmune, infectious, and inflammatory conditions) and may also occur in healthy individuals in varying prevalence. The lack of diagnostic specificity requires confirmation of positive ANA by more specific serologic tests. ANA (nuclear reactivity) positive patterns reported include centromere, homogeneous, nuclear dots, nucleolar, or speckled. ANA (cytoplasmic reactivity) positive patterns reported include reticular/AMA, discrete/GW body-like, polar/golgi-like, cytoplasmic speckled or rods and rings. All positive patterns are reported to endpoint titers (1:2560). Reported patterns may help guide differential diagnosis, although they may not be specific for individual antibodies or diseases. Mitotic staining patterns not reported. Negative results do not necessarily rule out SARD.

Ha (tyrosyl-tRNA synthetase) Ab	Negative	(Ref Interval: Negative)
	Ha antibody negative by line immunoassay. No band corresponding to 65 kDa observed by immunoprecipitation.	

Ks (asparaginyl-tRNA synthetase) Ab	Negative	(Ref Interval: Negative)
	Ks antibody negative by line immunoassay. No band corresponding to 65 kDa observed by immunoprecipitation.	

Zo (phenylalanyl-tRNA synthetase) Ab	Negative	(Ref Interval: Negative)
	Zo antibody negative by line immunoassay. No bands corresponding to 68 and 58 kDa observed by immunoprecipitation.	

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

VERIFIED/REPORTED DATES

Procedure	Accession	Collected	Received	Verified/Reported
SSA-52 (Ro52) (ENA) Antibody, IgG	25-022-102245	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
SSA-60 (Ro60) (ENA) Antibody, IgG	25-022-102245	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Smith/RNP (ENA) Ab, IgG	25-022-102245	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Jo-1 (Histidyl-tRNA Synthetase) Ab, IgG	25-022-102245	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
PL-12 (alanyl-tRNA synthetase) Antibody	25-022-102245	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
PL-7 (threonyl-tRNA synthetase) Antibody	25-022-102245	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
EJ (glycyl-tRNA synthetase) Antibody	25-022-102245	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
OJ (isoleucyl-tRNA synthetase) Antibody	25-022-102245	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
SRP (Signal Recognition Particle) Ab	25-022-102245	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Ku Antibody	25-022-102245	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
PM/Scl 100 Antibody, IgG	25-022-102245	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Fibrillarin (U3 RNP) Ab, IgG	25-022-102245	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Mi-2 (nuclear helicase protein) Antibody	25-022-102245	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
P155/140 Antibody	25-022-102245	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
TIF-1 gamma (155 kDa) Ab	25-022-102245	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
SAE1 (SUMO activating enzyme) Ab	25-022-102245	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
MDA5 (CADM-140) Ab	25-022-102245	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
NXP2 (Nuclear matrix protein-2) Ab	25-022-102245	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Myositis Panel Interpretive Data	25-022-102245	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Antinuclear Antibody (ANA), HEp-2, IgG	25-022-102245	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
ANA Interpretive Comment	25-022-102245	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Ha (tyrosyl-tRNA synthetase) Ab	25-022-102245	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Ks (asparaginyl-tRNA synthetase) Ab	25-022-102245	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Zo (phenylalanyl-tRNA synthetase) Ab	25-022-102245	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00

END OF CHART

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

ARUP LABORATORIES | 800-522-2787 | aruplab.com
500 Chipeta Way, Salt Lake City, UT 84108-1221
Jonathan R. Genzen, MD, PhD, Laboratory Director

Patient: Patient, Example
ARUP Accession: 25-022-102245
Patient Identifiers: 01234567890ABCD, 012345
Visit Number (FIN): 01234567890ABCD
Page 6 of 6 | Printed: 1/22/2025 2:15:30 PM
4848